155 related articles for article (PubMed ID: 26473142)
21. Molecular basis of progressive familial intrahepatic cholestasis 3. A proteomics study.
Guerrero L; Carmona-Rodríguez L; Santos FM; Ciordia S; Stark L; Hierro L; Pérez-Montero P; Vicent D; Corrales FJ
Biofactors; 2024 Jan; ():. PubMed ID: 38284625
[TBL] [Abstract][Full Text] [Related]
22. [Genetic cholestasis].
Ciocca M; Alvarez F
Arch Argent Pediatr; 2009 Aug; 107(4):340-6. PubMed ID: 19753442
[TBL] [Abstract][Full Text] [Related]
23. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects.
Davit-Spraul A; Gonzales E; Baussan C; Jacquemin E
Semin Liver Dis; 2010 May; 30(2):134-46. PubMed ID: 20422496
[TBL] [Abstract][Full Text] [Related]
24. Combined features of low phospholipid-associated cholelithiasis and progressive familial intrahepatic cholestasis 3.
Poupon R; Barbu V; Chamouard P; Wendum D; Rosmorduc O; Housset C
Liver Int; 2010 Feb; 30(2):327-31. PubMed ID: 19840255
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy.
Gonzales E; Gardin A; Almes M; Darmellah-Remil A; Seguin H; Mussini C; Franchi-Abella S; Duché M; Ackermann O; Thébaut A; Habes D; Hermeziu B; Lapalus M; Falguières T; Combal JP; Benichou B; Valero S; Davit-Spraul A; Jacquemin E
JHEP Rep; 2023 Oct; 5(10):100844. PubMed ID: 37701337
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model.
Weber ND; Odriozola L; Martínez-García J; Ferrer V; Douar A; Bénichou B; González-Aseguinolaza G; Smerdou C
Nat Commun; 2019 Dec; 10(1):5694. PubMed ID: 31836711
[TBL] [Abstract][Full Text] [Related]
27. Phenotypic variability in Tunisian PFIC3 patients harboring a complex genotype with a differential clinical outcome of UDCA treatment.
Khabou B; Mahjoub B; Barbu V; Balhoudi N; Wardani A; Sfar MT; Fakhfakh F
Clin Chim Acta; 2018 Nov; 486():122-128. PubMed ID: 30036524
[TBL] [Abstract][Full Text] [Related]
28. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression.
Degiorgio D; Crosignani A; Colombo C; Bordo D; Zuin M; Vassallo E; Syrén ML; Coviello DA; Battezzati PM
J Gastroenterol; 2016 Mar; 51(3):271-80. PubMed ID: 26324191
[TBL] [Abstract][Full Text] [Related]
29. Progressive familial intrahepatic cholestasis type-3 and multiple sclerosis: lessons from comorbidity.
De Masi R; Orlando S; De Donno A
Ann Clin Transl Neurol; 2019 Nov; 6(11):2347-2350. PubMed ID: 31568708
[TBL] [Abstract][Full Text] [Related]
30. A New Mutation Causing Progressive Familiar Intrahepatic Cholestasis Type 3 in Association with Autoimmune Hepatitis.
Oliveira HM; Pereira C; Santos-Silva E; Pinto-Basto J; Vizcaíno JR; Pessegueiro-Miranda H
Eur J Case Rep Intern Med; 2017; 4(2):000537. PubMed ID: 30755924
[TBL] [Abstract][Full Text] [Related]
31. Progressive Familial Intrahepatic Cholestasis Type 3 Homozygous Pathogenic Variant c.2906G>A in the ATP Binding Cassette Subfamily B Member 4 (ABCB4) Gene: A Case Report of an Unusual Presentation.
Alasmari BG; Rayees S; Alomari M; Elzubair L; Hamid Y
Cureus; 2022 Dec; 14(12):e32455. PubMed ID: 36644077
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic and Molecular Characteristics of Children with Progressive Familial Intrahepatic Cholestasis in South China.
Zhang W; Lin R; Lu Z; Sheng H; Xu Y; Li X; Cheng J; Cai Y; Mao X; Liu L
Pediatr Gastroenterol Hepatol Nutr; 2020 Nov; 23(6):558-566. PubMed ID: 33215027
[TBL] [Abstract][Full Text] [Related]
33. ABCB4 Gene Aberrations in Human Liver Disease: An Evolving Spectrum.
Reichert MC; Lammert F
Semin Liver Dis; 2018 Nov; 38(4):299-307. PubMed ID: 30357767
[TBL] [Abstract][Full Text] [Related]
34. In silico investigation of the impact of synonymous variants in ABCB4 gene on mRNA stability/structure, splicing accuracy and codon usage: Potential contribution to PFIC3 disease.
Khabou B; Siala-Sahnoun O; Gargouri L; Mkaouar-Rebai E; Keskes L; Hachicha M; Fakhfakh F
Comput Biol Chem; 2016 Dec; 65():103-109. PubMed ID: 27788395
[TBL] [Abstract][Full Text] [Related]
35. Elevated copper impairs hepatic nuclear receptor function in Wilson's disease.
Wooton-Kee CR; Jain AK; Wagner M; Grusak MA; Finegold MJ; Lutsenko S; Moore DD
J Clin Invest; 2015 Sep; 125(9):3449-60. PubMed ID: 26241054
[TBL] [Abstract][Full Text] [Related]
36. Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy.
Weber ND; Odriozola L; Ros-Gañán I; García-Porrero G; Salas D; Argemi J; Combal JP; Kishimoto TK; González-Aseguinolaza G
JHEP Rep; 2023 May; 5(5):100713. PubMed ID: 37096142
[TBL] [Abstract][Full Text] [Related]
37. Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy.
van der Woerd WL; van Mil SW; Stapelbroek JM; Klomp LW; van de Graaf SF; Houwen RH
Best Pract Res Clin Gastroenterol; 2010 Oct; 24(5):541-53. PubMed ID: 20955958
[TBL] [Abstract][Full Text] [Related]
38. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases.
Jacquemin E
Semin Liver Dis; 2001 Nov; 21(4):551-62. PubMed ID: 11745043
[TBL] [Abstract][Full Text] [Related]
39. Ductopenia and cirrhosis in a 32-year-old woman with progressive familial intrahepatic cholestasis type 3: A case report and review of the literature.
Tan YW; Ji HL; Lu ZH; Ge GH; Sun L; Zhou XB; Sheng JH; Gong YH
World J Gastroenterol; 2018 Nov; 24(41):4716-4720. PubMed ID: 30416319
[TBL] [Abstract][Full Text] [Related]
40. Prevention of Cholestatic Liver Disease and Reduced Tumorigenicity in a Murine Model of PFIC Type 3 Using Hybrid AAV-piggyBac Gene Therapy.
Siew SM; Cunningham SC; Zhu E; Tay SS; Venuti E; Bolitho C; Alexander IE
Hepatology; 2019 Dec; 70(6):2047-2061. PubMed ID: 31099022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
